Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
ABSTRACT Objective To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). Subjects and methods A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. Results From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). Conclusions Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes.
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Endocrinologia e Metabologia
2018
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000200149 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S2359-39972018000200149 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S2359-399720180002001492018-05-07Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapySúss,Shirlei Kugler AiçarMesa Jr.,Cleo OtavianoCarvalho,Gisah Amaral deMiasaki,Fabíola YukikoChaves,Carolina PerezFuser,Dominique CochatCorbo,RossanaMomesso,DeniseBulzico,Daniel A.Graf,HansVaisman,Fernanda Thyroid carcinoma radioiodine ablation low activity ABSTRACT Objective To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). Subjects and methods A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. Results From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). Conclusions Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes.info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArchives of Endocrinology and Metabolism v.62 n.2 20182018-03-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000200149en10.20945/2359-3997000000025 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Súss,Shirlei Kugler Aiçar Mesa Jr.,Cleo Otaviano Carvalho,Gisah Amaral de Miasaki,Fabíola Yukiko Chaves,Carolina Perez Fuser,Dominique Cochat Corbo,Rossana Momesso,Denise Bulzico,Daniel A. Graf,Hans Vaisman,Fernanda |
spellingShingle |
Súss,Shirlei Kugler Aiçar Mesa Jr.,Cleo Otaviano Carvalho,Gisah Amaral de Miasaki,Fabíola Yukiko Chaves,Carolina Perez Fuser,Dominique Cochat Corbo,Rossana Momesso,Denise Bulzico,Daniel A. Graf,Hans Vaisman,Fernanda Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
author_facet |
Súss,Shirlei Kugler Aiçar Mesa Jr.,Cleo Otaviano Carvalho,Gisah Amaral de Miasaki,Fabíola Yukiko Chaves,Carolina Perez Fuser,Dominique Cochat Corbo,Rossana Momesso,Denise Bulzico,Daniel A. Graf,Hans Vaisman,Fernanda |
author_sort |
Súss,Shirlei Kugler Aiçar |
title |
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_short |
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_full |
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_fullStr |
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_full_unstemmed |
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_sort |
clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mci for ablation or without radioactive iodine therapy |
description |
ABSTRACT Objective To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). Subjects and methods A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. Results From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). Conclusions Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes. |
publisher |
Sociedade Brasileira de Endocrinologia e Metabologia |
publishDate |
2018 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000200149 |
work_keys_str_mv |
AT sussshirleikugleraicar clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT mesajrcleootaviano clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT carvalhogisahamaralde clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT miasakifabiolayukiko clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT chavescarolinaperez clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT fuserdominiquecochat clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT corborossana clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT momessodenise clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT bulzicodaniela clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT grafhans clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT vaismanfernanda clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy |
_version_ |
1756441396730920960 |